UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.179

Sortiert nach

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy

Clinical cancer research, 2015-12, Vol.21 (24), p.5427-5433

2015

Volltextzugriff (PDF)

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

Oncotarget, 2017-02, Vol.8 (9), p.16052-16074

2017

Volltextzugriff (PDF)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

Cell cycle (Georgetown, Tex.), 2015-07, Vol.14 (14), p.2219-2221

2015

Volltextzugriff (PDF)

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

Clinical cancer research, 2008-08, Vol.14 (16), p.5000-5005

2008

Volltextzugriff (PDF)

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

Cancer letters, 2008-09, Vol.269 (1), p.7-17

2008

Volltextzugriff (PDF)

The yin and yang of nitric oxide in cancer progression

Carcinogenesis (New York), 2013-03, Vol.34 (3), p.503-512

2013

Volltextzugriff (PDF)

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer

Molecular cancer therapeutics, 2017-07, Vol.16 (7), p.1412-1420

2017

Volltextzugriff (PDF)

Role of artificial intelligence in the care of patients with nonsmall cell lung cancer

European journal of clinical investigation, 2018-04, Vol.48 (4), p.n/a

2018

Volltextzugriff (PDF)

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Cancer treatment reviews, 2017-02, Vol.53, p.111-119

2017

Volltextzugriff (PDF)

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Clinical cancer research, 2020-05, Vol.26 (10), p.2290-2296

2020

Volltextzugriff (PDF)

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Journal for immunotherapy of cancer, 2018-05, Vol.6 (1), p.39-39, Article 39

2018

Volltextzugriff (PDF)

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells

Journal of hematology and oncology, 2022-09, Vol.15 (1), p.1-134, Article 134

2022

Volltextzugriff (PDF)

Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

Cancer biology & therapy, 2019-08, Vol.20 (8), p.1047-1056

2019

Volltextzugriff (PDF)

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Journal of clinical oncology, 2010-10, Vol.28 (28), p.4339-4345

2010

Volltextzugriff (PDF)

Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer

International journal of molecular medicine, 2020-02, Vol.45 (2), p.315-323

2020

Volltextzugriff (PDF)

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

Cancer Immunology, Immunotherapy, 2017-01, Vol.66 (1), p.25-32

2017

Volltextzugriff (PDF)

Repurposing metformin for cancer treatment: current clinical studies

Oncotarget, 2016-06, Vol.7 (26), p.40767-40780

2016

Volltextzugriff (PDF)

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response

Clinical cancer research, 2019-11, Vol.25 (21), p.6452-6462

2019

Volltextzugriff (PDF)

Emerging therapeutic targets in bladder cancer

Cancer treatment reviews, 2015-02, Vol.41 (2), p.170-178

2015

Volltextzugriff (PDF)

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

British journal of haematology, 2015-05, Vol.169 (4), p.534-543

2015

Volltextzugriff (PDF)

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer

Clinical cancer research, 2017-04, Vol.23 (8), p.1891-1897

2017

Volltextzugriff (PDF)

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Blood, 2007-01, Vol.109 (2), p.500-502

2007

Volltextzugriff (PDF)

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer

Scientific reports, 2019-12, Vol.9 (1), p.19977-9, Article 19977

2019

Volltextzugriff (PDF)

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival

Clinical cancer research, 2017-11, Vol.23 (21), p.6650-6660

2017

Volltextzugriff (PDF)

1 – 25 von 1.179

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.041)
Mit Volltextzugriff
(1.104)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.156)
Japanisch
(97)
Spanisch
(17)
Französisch
(4)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(614)
Life Sciences & Biomedicine
(590)
Humans
(579)
Oncology
(359)
Biological And Medical Sciences
(291)
Medical Sciences
(291)
Middle Aged
(283)
Female
(273)
Male
(259)
Adult
(244)
Aged
(242)
Hematology
(214)
Treatment Outcome
(168)
Hematologic And Hematopoietic Diseases
(164)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(156)
Pharmacology. Drug Treatments
(138)
Antineoplastic Agents - Therapeutic Use
(136)
Antineoplastic Agents
(132)
Aged, 80 And Over
(118)
Prognosis
(108)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

The yin and yang of nitric oxide in cancer progression

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer

Role of artificial intelligence in the care of patients with nonsmall cell lung cancer

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells

Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

Repurposing metformin for cancer treatment: current clinical studies

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response

A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma

Emerging therapeutic targets in bladder cancer

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival

Suchergebnisse filtern